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Background: Identification of novel, highly penetrant, breast cancer susceptibility genes will require the application
of additional strategies beyond that of traditional linkage and candidate gene approaches. Approximately one-third
of inherited genetic diseases, including breast cancer susceptibility, are caused by frameshift or nonsense mutations
that truncate the protein product [1]. Transcripts harbouring premature termination codons are selectively and
rapidly degraded by the nonsense-mediated mRNA decay (NMD) pathway. Blocking the NMD pathway in any given
cell will stabilise these mutant transcripts, which can then be detected using gene expression microarrays. This
technique, known as gene identification by nonsense-mediated mRNA decay inhibition (GINI), has proved
successful in identifying sporadic nonsense mutations involved in many different cancer types. However, the
approach has not yet been applied to identify germline mutations involved in breast cancer. We therefore
attempted to use GINI on lymphoblastoid cell lines (LCLs) from multiple-case, non- BRCA1/2 breast cancer families
in order to identify additional high-risk breast cancer susceptibility genes.
Methods: We applied GINI to a total of 24 LCLs, established from breast-cancer affected and unaffected women
from three multiple-case non-BRCA1/2 breast cancer families. We then used Illumina gene expression microarrays to
identify transcripts stabilised by the NMD inhibition.
Results: The expression profiling identified a total of eight candidate genes from these three families. One gene,
PPARGC1A, was a candidate in two separate families. We performed semi-quantitative real-time reverse transcriptase
PCR of all candidate genes but only PPARGC1A showed successful validation by being stabilised in individuals with
breast cancer but not in many unaffected members of the same family. Sanger sequencing of all coding and splice
site regions of PPARGC1A did not reveal any protein truncating mutations. Haplotype analysis using short tandem
repeat microsatellite markers did not indicate the presence of a haplotype around PPARGC1A which segregated
with disease in the family.
Conclusions: The application of the GINI method to LCLs to identify transcripts harbouring germline truncating
mutations is challenging due to a number of factors related to cell type, microarray sensitivity and variations in
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Germline mutations in either one of the two major
breast cancer tumour suppressor genes, BRCA1 or
BRCA2, confer a 60-85% lifetime risk of breast cancer
but explain only around 20% of the breast cancer cases
that have a family history of the disease [2-8]. However,
almost 70% of breast cancer families with four or more
cases of early onset breast cancer under the age of 60
show no convincing evidence of linkage to BRCA1 or
BRCA2 [9]. Nonetheless, for women without mutations
in BRCA1 or BRCA2, family history remains a strong
predictive risk factor for breast cancer [10-12]. This un-
explained familial aggregation of the disease suggests the
presence of additional high-risk, breast cancer suscepti-
bility genes, particularly in non-BRCA1/2 families with
many cases of early onset breast cancer [13].
The largest genome-wide breast cancer linkage study
since the identification of BRCA2, conducted on 149
non-BRCA1/2 breast cancer families by the Breast Can-
cer Linkage Consortium, failed to find any significant
linkage signals [14]. However, the selection criteria of
the families, differences in the population background,
or clinical and genetic heterogeneity might determine
the power to detect a linkage signal. Rosa- Rosa et al
performed linkage analysis in 41 breast-cancer Spanish
families and found a significant linkage signal (HLOD
score 3.55) at 21q22. They also found a HLOD of 3.13
on the 3q25 region [15] in a subset of 13 families with
bilateral breast cancer. Collectively, the published link-
age studies [15-17] do not provide conclusive evidence
that high risk BRCA-like genes exist, but certainly indi-
cate that if they do, their mutations would only account
for a small fraction of the non-BRCA1/2 families. Candi-
date gene approaches for mutation screening rely on a
priori information about biological gene function and
are thus limited by how much is known about the biol-
ogy of the disease. Identification of rare mutations in
highly penetrant breast cancer susceptibility genes will
therefore require the application of more novel strategies
beyond that of traditional linkage and candidate gene
approaches. A strategy for disease gene identification by
NMD inhibition (GINI) utilising gene expression profil-
ing has been developed to identify dysregulated tran-











A 20 19 5 26, 34, 43, 47, 64
B 24 21 3 39, 39, 41
C 19 19 3 36, 44, 56thereby allowing this approach to be used to prioritise
genes for mutation analysis [18].
The Breast Cancer Information Core database (BIC;
http://research.nhgri.nih.gov/bic/; version modified
September 2010) states that almost 50% of all reported
BRCA1 mutations and about 30% of reported BRCA2
mutations are either frameshift or nonsense mutations,
thus it is reasonable to expect that protein truncating
mutations will be common in any other highly pene-
trant breast cancer susceptibility genes. The NMD
pathway selectively and rapidly degrades mutant mes-
senger RNAs harbouring premature termination
codons (PTCs) [19-21]. Therefore, blocking the NMD
pathway will stabilise these mutant transcripts, which
can then lead to the identification of potential tumour
suppressor genes that contain nonsense mutations
[18,22]. Such genome-wide screens for transcripts har-
bouring truncating mutations has proved successful in
identifying sporadic nonsense mutations involved in
colon cancer [18,19,23,24], prostate cancer [25,26],
melanoma [27], mantle cell lymphoma [28] and clear
cell renal cell carcinoma [29]. However, the approach
has not yet been applied to identify germline mutations
involved in breast cancer. In an attempt to identify add-
itional high-risk genes involved in familial breast can-
cer, we have applied this disease-gene identification
technique to affected and unaffected members of
multiple- case non-BRCA1/2 breast cancer families.
Methods
Selection of non-BRCA1/2 breast cancer families
The Kathleen Cuningham Foundation Consortium for
Research into Familial Breast Cancer (kConFab; http://
www.kconfab.org) provides a comprehensive resource
upon which researchers can draw data and biospecimens
for peer-reviewed, ethically- approved funded research
projects on familial aspects of breast cancer. We selected
three families (Family A, B and C) for use in GINI
(Table 1), in which no BRCA1 or BRCA2 mutations had
been found, and which had Manchester scores >19
[30,31] suggesting a high probability of having a mutation
in a breast cancer susceptibility gene. For each family,
there were at least three LCLs from women affected with











3 32, 38, 63 48
4 26, 28, 57, 58 42
6 41, 45, 62, 68, 70, 72 54
Johnson et al. BMC Cancer 2012, 12:246 Page 3 of 12
http://www.biomedcentral.com/1471-2407/12/246women who were unaffected at ages 26–72. Ethical
approvals were obtained from the Human Research Ethics
Committees of the Queensland Institute of Medical Re-
search and the Peter MacCallum Cancer Centre. Written
informed consent was obtained from each participant.
Cell lines
We used the colon cancer cell line, HT29, which con-
tains a truncating mutation (c.931C>T p.Q311X) in
one allele of the SMAD4 gene and a deletion of the
other allele, as a positive control, as well as two positive
control LCLs (BRCA1 c.2681_2682delAA and BRCA2
c.539_541insAT). These truncating mutations occur >55
nucleotides upstream from the final exon of each gene
and are thus expected to undergo nonsense-mediated
mRNA decay. To identify putative novel, breast cancer
susceptibility genes by GINI, we used 24 LCLs estab-
lished from patients affected with breast cancer and un-
affected individuals from three non-BRCA1/2 breast
cancer families.
Gene inhibition of nonsense mediated decay (GINI)
Twenty-four hours prior to caffeine treatment, we
seeded HT29 cells into two 75cm2 cell culture flasks,
each containing 1x106 cells in 10mls of tissue culture
medium (RPMI-1640 + 10% FBS). We then added fresh
medium containing 10mM caffeine (Sigma-Aldrich, St.
Louis, MO, USA) to one flask and fresh medium without
caffeine to the control flask. After four hours of incuba-
tion at 37°C, we removed the medium from both flasks
and washed the cells twice with phosphate-buffered sa-
line (PBS). We then added normal medium to the un-
treated control flask and treated the other flask for a
further four hours with 10mM caffeine medium. We
then removed the media from both flasks and washed
the cells twice with PBS before storing the cells at −80°C
until RNA extraction. We repeated this process ten
times to ensure repeatability of results. We then per-
formed semi-quantitative real-time reverse transcriptase
(RTPCR) of SMAD4 to confirm stabilisation of the target
gene after caffeine treatment, and cRNA from four ran-
domly selected replicates were then hybridised to the
Illumina HumanHT-12 v3 gene expression arrays.
In order to determine the optimal caffeine concentra-
tion for treating LCLs, we treated 3.5x106 LCLs with
2.5mM, 5mM, 7.5mM, 10mM or 15mM caffeine (Sigma-
Aldrich) for two lots of four-hour incubations at 37°C in
the same GINI process described above for HT29 cells.
We determined the optimal concentration by semi-
quantitative real-time RT-PCR of BRCA1 and BRCA2
(Additional File 1) and then performed three technical
replicates of GINI on the positive control LCLs on dif-
ferent days, and hybridised the cRNA to Illumina
HumanHT-12 v3 gene expression arrays.GINI on LCLs from non-BRCA1/2 breast cancer families
Having optimised the GINI method on positive control
LCLs with BRCA1 or BRCA2 mutations, we applied it to
LCLs from 11 affected and 13 unaffected individuals
from three non-BRCA1/2 breast cancer families, in par-
allel with positive control HT29 cells. We performed
three technical replicates for each sample on different
days and then hybridised cRNA from caffeine-treated
and untreated control samples to Illumina HumanHT-
12 v3 gene expression arrays.
Semi-quantitative real-time reverse transcriptase PCR
(RT-PCR) and expression array profiling
We extracted total RNA from frozen cell pellets using the
RNeasy RNA Extraction Kit (Qiagen, Hilden, Germany) as
per the manufacturer’s instructions. We used semi-
quantitative real-time reverse transcriptase PCR (RT-
PCR) to validate the expression of the target genes in
the positive controls and of the candidate genes found
by the GINI method. Primer sequences are provided
in Additional File 2. We synthesised cDNA from 1μg
of total RNA in a reaction volume of 20μl using oli-
godT and Superscript III (Invitrogen) according to
manufacturer’s instructions. The cDNA reactions
were then diluted to 200μl (1:10) in RNase/DNase-
free water. We performed semi-quantitative real-time
RT-PCR amplifications in quadruplet on the LightCy-
cler480 (Roche) machine using 3.75μl SYBR Green
PCR Master Mix (Invitrogen) and 0.33μM forward and
reverse primers in a total reaction volume of 7.5μl,
using the glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) gene as a reference. We normalised the
comparative threshold-cycle (Ct) of signal intensities
of amplified product to that of GAPDH calibrating to
the matched untreated control of each sample using
the LightCycler480 software program (Roche Diag-
nostics Corp., Indianapolis, IN, USA).
For the expression profiling, we prepared biotiny-
lated cRNA from 450ng of total RNA using the Illu-
minaTotalPrep RNA Amplification Kit (Ambion,
Austin, TX, USA) and hybridised 750ng cRNA per
sample to HumanHT-12 v3 Expression BeadChips
(Illumina Inc., San Diego, CA, USA) as per the
Whole-Genome Gene Expression Direct Hybridisa-
tion Assay protocol. We collated expression data
using BeadStudio Version 1.5.1.3 (Illumina Inc.) and
then quantile normalised the raw data using the R-
Bioconductor LUMI package [32]. Microarray data
were submitted to Gene Expression Omnibus (GEO)
[33] and are accessible through GEO (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE37210).
To identify differentially expressed genes, between
each caffeine treated sample to its own untreated con-
trol over three technical replicates, we implemented a
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Bioconductor LIMMA package [34]. We considered
genes with Benjamini and Hochberg adjusted P-values
less than 5% that also have a greater than 50% chance of
being differentially expressed (positive B- statistic) as
having statistically significant changes in their expres-
sion profiles. We imported differentially expressed
genes into GeneSpring v10.0 (Agilent Technologies) for
visualisation and further analysis.
We defined genes that were differentially expressed
between all untreated and all caffeine treated samples as
“global caffeine response” genes. These genes are un-
likely to contain truncating mutations in breast cancer
susceptibility genes but are more likely to be expressed
in response to caffeine or be naturally occurring NMD
targets.
For each family, we selected candidate genes for semi-
quantitative real-time RT-PCR validation and mutations
screening that were upregulated after caffeine treatment
in the individuals affected with breast cancer but were
not differentially expressed after caffeine treatment in
their unaffected family members, and therefore not part
of the “global caffeine response” gene list.
Sequence analysis
We sequenced the exonic and flanking splice sites of the
one candidate gene we identified by GINI in the relevant
family. We amplified 500ng DNA by polymerase chain
reaction (PCR) with 1X PCR Buffer, 2.5mM MgCl2,
0.2mM dNTP, 0.25μM forward and reverse primer, 0.4μl
AmpliTaq Gold in a total reaction volume of 50μl. We
then purified the PCR products using the QIAquick
PCR Purification Kit Spin Protocol (Qiagen) prior to se-
quencing according to manufacturer’s instructions using
BigDye Terminator v3.1 and an ABI 3100 Genetic Ana-





















Figure 1 Stabilisation of SMAD4 mRNA in HT29 cells after caffeine (10
sample has been normalised to the housekeeping gene, GAPDH, and calibr
the mean of four technical replicates of each PCR reaction.Haplotyping around the PPARGC1A region
We used a total of six short tandem repeat microsatellite
markers from a 2Mb region around PPARGC1A to
haplotype around the PPARGC1A gene in members of
Family B. We selected four markers (D4S3017, D4S2953,
D4S425, D4S23013) (deCODE Genetics; http://www.de-
code.com) and designed two (19xTA and 20xTG) more
around short tandem repeats within the DNA sequence
of PPARGC1A and labelled either the forward or reverse
primer with a 6-FAM label. We amplified 500ng DNA
by polymerase chain reaction (PCR) with 1X PCR Buffer,
2.5mM MgCl2, 0.2mM dNTP, 0.25μM forward and re-
verse primer, 0.4μl AmpliTaq Gold in a 50μl final vol-
ume. Amplified PCR products were diluted 1:800 with
Hi-Di formamide/500 LIZ size standard mix (formamide
to size standard ratio of 67:1) (Applied Biosystems) and
the mixture was then denatured for 5 min at 95°C. The
samples were separated in an ABI PRISM3700 DNA Se-
quencer and subjected to the fragment analysis protocol.
Allele scoring was performed using the GeneMapper 4.0
software (Applied Biosystems).Results
Optimisation of GINI
We used HT29 cells to test the robustness of the GINI
technique with caffeine treatment. Results from semi-
quantitative real-time RT-PCR validation of ten replicate
experiments identified a consistent 2.5- to 3.7-fold upre-
gulation of SMAD4 mRNA after 10mM caffeine treat-
ment (Figure 1). Microarray results of three replicates
identified a total of 553 probes corresponding to 495
genes that were significantly differentially expressed ≥2-
fold between untreated and caffeine-treated HT29 cells.
When sorted by adjusted P-value, SMAD4 ranked as the
48th most differentially expressed gene and the 28th most7 8 9 10
Untreated
Caffeine Treated
mM) treatment measured by qRT-PCR. Each caffeine treated
ated to its untreated equivalent. Error bars represent standard error of
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value = 7.83-E07; B-statistic = 12.94).
In parallel with positive control HT29 cells, we treated
LCLs with known BRCA1 or BRCA2 mutations with a
caffeine concentration gradient and used semi-
quantitative real-time RT-PCR to find the concentration
that best stabilises their respective target genes (Add-
itional File 1). The highest level of target gene stabilisa-
tion in the LCLs was 2.4-fold at 7.5mM caffeine. We
repeated the GINI experiments a total of three times for
the BRCA1 and BRCA2 cell lines, and each replicate of
every cell line showed at least a 1.5-fold stabilisation of
their respective target genes after treatment with 7.5mM
caffeine (Figure 2).Identifying candidate breast cancer susceptibility genes
by GINI in nonBRCA1/2 breast cancer families
We applied GINI, with a caffeine concentration of
7.5mM, to 24 LCLs from three non-BRCA1/2 families.
We identified a set of 6,520 global caffeine response”
genes which were differentially expressed (adjusted
P-value< 0.0006 and B-statistic> 0) between untreated
and caffeine treated samples from all individuals com-
bined from the three families. Of these “global caffeine
response” genes, 1,364 and 292 genes changed more than
1.5- and 2-fold after caffeine treatment, respectively.
We identified candidate protein truncated transcripts
within each family as those with statistically significant
increased expression after caffeine treatment in affected
individuals of that family, but not in unaffected indivi-
duals of the other two families, and which were not part
of the “global caffeine response” (Figure 3). We identified
a total of two, two and five candidate genes for Family A,
B and C, respectively (Table 2). Interestingly, only one
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Figure 2 Stabilisation of target genes in HT29, BRCA1 and BRCA2 pos
Three experimental replicates of the GINI method were performed on HT2
LCLs. qRT-PCR results indicate that each experimental replicate shows at le
7.5mM caffeine. Each sample has been normalised to the housekeeping ge
represent standard error of the mean of four technical replicates of each Pcoactivator-1 α (PPARGC1A), was identified as a candi-
date in more than one family.Semi-quantitative real-time RT-PCR and sequencing of
candidate breast cancer susceptibility genes
We tried to validate all nine candidate genes in with
semi-quantitative real-time RT-PCR but only PPARGC1A
showed consistent stabilisation of mRNA transcript
across replicates of Family B in individuals affected by
breast cancer and not in their healthy family members
(Figure 4 and Additional File 3-9, Additional File 4, Add-
itional File 5, Additional File 6, Additional File 7, Add-
itional File 8). Primer sequences are provided in
Supplementary Table 1. The youngest individual in Family
B (individual 4: aged 26) showed statistically signifi-
cant stabilisation of the PPARGC1A transcript in two out
of three experimental replicates, suggesting that this indi-
vidual may be a carrier for a family-specific breast cancer
mutation but has not yet developed disease. However, se-
quencing of all coding regions in all affected and un-
affected family members and flanking splice sites did not
reveal any protein truncating mutations in PPARGC1A.
We identified three coding (rs2970847, rs3755863 and
rs8192678) and one non-coding (rs2946385) single nu-
cleotide polymorphisms (SNPs). The only variant identi-
fied that was not listed in dbSNP as a common
polymorphism was IVS7delT (Figure 5). However, this
variant was found in all members sequenced including
affected and unaffected individuals. Furthermore, Human
Splicing Finder [35] suggested that this intronic variant
has no effect on splicing. Haplotype analysis using short
tandem repeat microsatellite markers spanning 2Mb
around PPARGC1A showed no evidence of a haplotype
that might carry a protein truncating mutations segregat-
ing with disease within the family (Figure 5).Untreated Caffeine
Experiment 3
SMAD4 in HT29 cells
BRCA1 in BRCA1 cells
BRCA2 in BRCA2 cells
itive control cell lines after GINI with caffeine (7.5mM) treatment.
9 cells, BRCA1 c.2681_2682delAA and BRCA2 c.539_541insAcontrol
ast a 1.5-fold stabilisation of all three target genes after treatment with























response” = Genes 
differentially 
expressed after 
caffeine treatment in 
all individuals
Genes differentially 
expressed after caffeine 
treatment in affected 
individuals
Upregulated genes selected for 
validation by qRT-PCR and 
mutation screening.
Family A Family B Family C
Figure 3 Identification of candidate breast cancer susceptibility genes for mutation screening in multiple-case non-BRCA1/2 breast
cancer families. For each family, candidate genes included those that were upregulated after caffeine treatment in individuals affected with
breast cancer but not in their unaffected family members and also not part of the “global caffeine response” gene list.
Table 2 Candidate genes identified by GINI analysis
Family Gene Name Fold Change Adjusted P-value B-statistic
A WNT5A 1.14 0.005560 0.04
RAB3B 1.17 0.004254 0.33
B PPARGC1A 1.19 0.001226 4.23
CD14 1.19 0.001875 1.19
C PPARGC1A 1.41 3.00E-11 25.02
METRNL 1.44 0.001146 2.51
BMP6 1.43 3.61E-05 6.67
PRDM1 1.25 0.000314 4.04
GRSF1 1.69 0.007637 0.23
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In an attempt to identify germline mutations in add-
itional high risk breast cancer susceptibility genes, we
have optimised and applied the GINI method on lym-
phoblastoid cell lines derived from the blood of women
from multiple-case non- BRCA1/2 breast cancer fam-
ilies. By using positive control cell lines with known
truncating mutations, we have determined the optimal
concentration of caffeine that results in significant stabil-
isation of target genes, which is suggestive of successful
inhibition of the nonsense-mediated mRNA decay path-
way. Microarray analysis of the transcripts stabilised
after NMD inhibition by caffeine treatment in women
affected with breast cancer compared to their unaffected
relatives identified a total of eight different genes across
three families. One gene, peroxisome proliferator- acti-
vated receptor-γ coactivator-1 α (PPARGC1A), was a
candidate gene in two families and was the only breast
cancer susceptibility candidate gene that we coulddemonstrate by semi-quantitative real-time RT-PCR as
being consistently upregulated after GINI in affected
































































Figure 4 Stabilisation of PPARGC1A mRNA in the lymphoblastoid cell lines (LCLs) of individuals from Family B after caffeine (7.5mM)
treatment measured by semi-quantitative real-time RT-PCR. PPARGC1A mRNA is stabilised in family members affected by breast cancer and
not in unaffected family members, with the exception of Person 4. Each sample has been normalised to the housekeeping gene, GAPDH, and
calibrated to the lowest expressing untreated sample. Standard error bars represent standard error from the mean of four technical replicates for
each PCR reaction.
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http://www.biomedcentral.com/1471-2407/12/246PPARGC1A is a master transcriptional regulator of
mitochondrial oxidative phosphorylation and cellular en-
ergy metabolism. The gene is expressed in a broad range
of tissues with higher levels of expression detected in tis-
sues with high oxidative capacity, such as heart, skeletal
muscle, brown adipocyte, kidney and brain [36-38].
Upregulation of PPARGC1A in response to oxidative
stress can suppress the production of reactive oxygen
species [39]. PPARGC1A also plays an important role as
an estrogen receptor coactivator in the estrogen receptor
(ER) pathway by binding and enhancing transactivation
of estrogen receptor alpha (ERα) in a ligand-dependent
manner [40,41]. Persistent estrogen mediated mitogen
signalling of ERα has been known to stimulate thegrowth of a large proportion of breast cancers [42-45].
In fact, over half of all breast cancers overexpress ERα
[46]. An association study of ~800 BRCA1/2 mutation-
negative familial breast cancer cases and over 1,000 con-
trols from Germany found some evidence that the
PPARGC1A Thr612Met polymorphism might be a risk
factor for familial breast cancer (OR= 1.35, 95% CI 1.00-
1.81, P= 0.049), high-risk familial breast cancer (OR=
1.51, 95% CI 1.08-2.12, P= 0.017) and bilateral familial
breast cancer (OR= 2.30, 95% CI 1.24-4.28, P= 0.009)
[47]. However, haplotype analysis did not identify any
additional association with familial breast cancer [47].
Although, we did not identify any truncating muta-
tions in the coding or splice site regions of PPARGC1A,
AB Exon 6
Figure 5 Pedigree of Family B (A) and sequencing chromatogram of PPARGC1A IVS-7delT variant (B). GINI experiments were performed
on the LCLs derived from individuals marked with red circles. The red coloured numbers correspond to the person number in Figure 4. Upward
arrows indicate individuals that showed stabilisation of the PPARGC1A transcript. The IVS-7delT variant (B) is located seven base pairs upstream
from the start of exon 6 and was found in both affected and unaffected members of Family B as indicated by stars in the pedigree.
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unaffected individuals of two families. However, haplo-
typing analysis around PPARGC1A did not identify a
haplotype that segregated with disease in either family,
which may contain a cryptic, deeply intronic, mutation
that causes protein truncation.
Caffeine can impact on the alternative splicing of a
subset of cancer-associated genes [48]. For example, caf-
feine can result in alternatively spliced isoforms of
chaperonin- containing TCP1 subunit 3 (CCT3), asparaginesynthetise (ASNS), COMM-domain containing 5
(COMMD5), ATP binding cassette subfamily F member 2
(ABCF2), SLC39A1/ZIRTL, and yippee-like 5 gene (YPEL5)
being expressed. Exposure of HeLa cells to caffeine can also
result in differential expression of 40 cancer-associated gene
(for example, KLF6, SC35, CCT3, ASNS, COMMD5,
ABCF2, YPEL5) isoforms [48], although it is worth noting
that different patterns of gene expression result from differ-
ing concentrations of caffeine [49]. Nevertheless, even
though increased stability of mutant RNA is suggested to
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increased stability of the mutant transcript and the selective
depletion of the normal transcript [50]. Therefore, if NMD
inhibition by caffeine treatment did result in the stabilisa-
tion of one transcript and the reduction of another isoform,
then unless the probes present on the microarray can dis-
tinguish between these isoforms, the net change in gene ex-
pression may not have been detected on the array platform.
Furthermore, nonsense codons can reduce the abundance
of nuclear mRNA without affecting the abundance of pre-
mRNA or the half-life of cytoplasmic mRNA [51] and this
might further reduce the sensitivity of GINI.
In order to acquire a more selective list of nonsense
transcripts for a particular cell line, it may be necessary
to combine the results of multiple different methods of
NMD inhibition: 1) siRNA against UPF1 [52,53], 2) caf-
feine treatment, and 3) emetine treatment, which inhi-
bits the progression of the ribosome along the mRNA
[29,54]. A major problem with using the GINI approach
for identifying pathogenic mutations in yet-unidentified
high-risk breast cancer genes in the germline DNA of
individuals affected with breast cancer is that the muta-
tion is expected to be present in a heterozygous state (at
least, in an autosomal dominant disorder). The stabilisa-
tion of only one allele reaches the sensitivity limits of
gene expression microarrays. Therefore, genes that may
have been mutated but are expressed at a moderate to
low level may have been excluded from detection.
Tumour suppressor genes are usually inactivated dur-
ing the process of tumorigenesis by a two-step process
involving an inactivating mutation in the target gene
accompanied by loss of the wildtype allele. However,
in LCLs established from peripheral blood mono-
nuclear leukocytes, the normal wildtype allele could
mask the effects of GINI on the mutated allele thus
reducing the efficiency of GINI [55]. Furthermore,
LCLs may not provide an accurate representation of
genes that are active in breast tissue, and if the puta-
tive breast cancer susceptibility gene is not expressed
in LCLs then GINI will not work to identify suscepti-
bility genes.
There is also evidence to suggest that NMD efficiency
varies between different people with the same mutation
[56,57], between different tissue types within an organ-
ism [58,59], and even between different strains of the
same cell type [60]. It is possible that variable efficien-
cies of NMD can influence the clinical outcome of
hereditary and acquired genetic disease and thus act as
a genetic modifier of human genetic diseases.
Inhibition of the nonsense-mediated mRNA decay
pathway followed by microarray analysis has been suc-
cessfully applied to cancer cell lines to identify protein
truncating mutations that may underlie sporadic formsof cancer [19,23,25-29,54]. The GINI method has re-
cently been applied to the LCLs from six prostate can-
cer patients and their healthy brothers in order to
identify susceptibility genes in hereditary prostate can-
cer [55]. However, despite sequencing 17 candidate
genes, no truncating mutations were found. The GINI
method has also failed to identify putative tumour sup-
pressor genes in gastric cancer cell lines with siRNA
against UPF1 [61]. It is commonly reported that the
GINI strategy leads to a high number of false positives
[19,21,23,26-28,55,61,62]. The novelty of our approach
is the ability to identify transcripts stabilised by NMD
inhibition in multiple breast cancer patients within a
family and compare this gene list to the transcripts
that are stabilised in multiple unaffected members of
the same family in an attempt to reduce the number
of false positive hits. Despite this analysis identifying
few candidate genes per family, we did not identify
any detectable nonsense mutations. Therefore, our
GINI analysis also results in a high number of false
positives. However, it is also possible that the mechan-
ism underlying susceptibility to breast cancer in non-
BRCA1/2 families may not be due to truncating muta-
tions in susceptibility genes.Conclusion
In summary, we applied the gene identification by
nonsense-mediated mRNA decay inhibition (GINI)
strategy to lymphoblastoid cell lines established from
the blood of affected and unaffected members of three
multiple-case non-BRCA1/2 breast cancer families but
we did not identify any nonsense mutations that may
underlie the breast cancer risk in any of the three
families investigated. The application of the GINI
method to identify germline mutations is challenging
due to limitations including microarray sensitivity in
detecting small fold changes, and because of individ-
ual variations in nonsense-mediated mRNA decay effi-
ciency [24,50,56,59,60,63].
With the plummeting costs of next generation se-
quencing technologies, sequencing of whole exomes
and genomes is becoming a much more attractive
method to identify rare, yet high risk, pathogenic
mutations underlying human genetic disease.Additional files
Additional file 1: Optimisation of caffeine concentration for
lymphoblastoid cell lines (LCLs). Level of mRNA stabilisation for two
biological replicates of SMAD4 in HT29 (A), BRCA1 in BRCA1
c.2681_2682delAA LCL (B), BRCA2 in BRCA2 c.6275_6276delTT LCL (C) and
BRCA2 in BRCA2 c.539_541insAT LCL (D) after treatment with different
Johnson et al. BMC Cancer 2012, 12:246 Page 10 of 12
http://www.biomedcentral.com/1471-2407/12/246concentrations of caffeine (untreated - 15mM). Error bars represent
standard error of the mean.
Additional file 2: Primer sequences used for semi-quantitative real-
time reverse transcriptase PCR of candidate genes identified with
the GINI technique.
Additional file 3: Stabilisation of WNT5A mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family A after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
Additional file 4: Stabilisation of RAB3B mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family A after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
Additional file 5: Stabilisation of CD14 mRNA in the lymphoblastoid
cell lines (LCLs) of individuals from Family B after caffeine (7.5mM)
treatment measured by semi-quantitative real-time RT-PCR. Each
sample has been normalised to the housekeeping gene, GAPDH, and
calibrated to the lowest expressing untreated sample to show variation
in transcript expression across individuals. Standard error bars represent
standard error from the mean of four technical replicates for each PCR
reaction.
Additional file 6: Stabilisation of PPARGC1A mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family C after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
Additional file 7: Stabilisation of METRNL mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family C after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
Additional file 8: Stabilisation of BMP6 mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family C after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
Additional file 9: Stabilisation of GRSF1 mRNA in the
lymphoblastoid cell lines (LCLs) of individuals from Family C after
caffeine (7.5mM) treatment measured by semi-quantitative real-
time RT-PCR. Each sample has been normalised to the housekeeping
gene, GAPDH, and calibrated to the lowest expressing untreated sample
to show variation in transcript expression across individuals. Standard
error bars represent standard error from the mean of four technical
replicates for each PCR reaction.
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